Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs) Kerstin Nagel-WolfrumFabian MöllerUwe Wolfrum Leading Article 17 February 2016 Pages: 49 - 74
Trastuzumab in the Treatment of Breast Cancer Sofia MaximianoPaulo MagalhãesManuel Morgado Review Article 18 February 2016 Pages: 75 - 86
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates Pawel RobakTadeusz Robak Review Article 29 February 2016 Pages: 87 - 93
Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis Elie KassoufSamer TabchiMustapha Tehfe Review Article 29 February 2016 Pages: 95 - 104
The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents Alberto MiglioreEmanuele BizziDavide Integlia Systematic Review 23 February 2016 Pages: 105 - 115
Expression and Purification of Neurotrophin-Elastin-Like Peptide Fusion Proteins for Neural Regeneration Tamina JohnsonPiyush Koria Original Research Article 28 January 2016 Pages: 117 - 127
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells Monika Paul-SamojednyAdam PudełkoJan Kowalski Original Research Article 22 February 2016 Pages: 129 - 144
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice Paul S. CalaraJenny M. NorlinMarcus Schmitt-Egenolf Original Research Article 16 February 2016 Pages: 145 - 151
Tbo-Filgrastim: A Review in Neutropenic Conditions Hannah A. BlairLesley J. Scott Adis Drug Evaluation 29 March 2016 Pages: 153 - 160